Dear Editor,

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a global pandemic that severely threatens global health with concordant economic damage. However, there is currently no clinically approved vaccines or drugs against COVID-19 (Lu et al., 2020). SARS-CoV-2 main protease (Mpro, also called 3C-like protease, 3CLpro) mediates the proteolytic processing of large replicase polyprotein 1a (pp1a) and pp1ab into non-structural proteins (NSPs) at eleven conservative sites (Zumla et al., 2016). Thus, Mpro is of considerable interest as a drug target in the treatment of COVID-19 since the proteolytic activity of this viral protease is essential for viral replication. Mutational and structural studies have identified substrate binding site and active site of Mpro that confers specificity for the Gln-P1 substrate residue in the active conformation (Jin et al., 2020a; Hilgenfeld, 2014; Yang et al., 2003). Recent structures of Mpro for SARS-CoV-2 have been solved in complexes with natural products and novel inhibitors very recently (Dai et al., 2020; Jin et al., 2020b). However, a structural description of these sites in the apo state has remained elusive.

Here we report the first structure of Mpro for SARS-CoV-2 in the apo state under conditions close to the physiological state (pH 7.5) to an overall resolution of 1.9 Å (Table S1 in...
Supporting Information). This structure highlights several key findings which will help guide drug discovery and functional studies (Figure 1A). Specifically, we found the Mpro forms a dimer in the crystal and has two distinct dimer interfaces, which are located in the N-terminal domain (residues 1–11) and the oxyanion loop (residues 137–145).
Oxyanion holes, like the one found here, are classically found in proteases and are often formed by amides or positively charged residues (in this case predominantly made of histidine). They are crucial for stabilizing transition states during enzyme catalysis, thus facilitating enzyme activity. Comparison of our Mₚro structure in the apo state to the previously reported Mₚro structure in complex with an inhibitor revealed a backbone (Ca) RMSD of 0.92 Å showing a similar overall structure (Figure 1C) (Yang et al., 2003; Dai et al., 2020; Jin et al., 2020b). As in ligand-bound Mₚro structures, the protein consists of N-finger and three other domains that bind an inhibitor at the cleft between domains I and II (Figure 1A).

There were, however, several notable local differences between the apo and ligand-bound structures. Electron density of the N-finger (residues 1–2), oxyanion loop (residues 141–142), C-terminal domain (residues 299–306) were insufficient for backbone tracing, suggesting the flexibility of this region in the apo state. In addition, electron densities of side chains Phe140 and Glu166, which are key residues involved in the substrate binding are missing at this high resolution that may reflect different conformation of the apo state (Figure 1D).

As mentioned, the oxyanion hole composed of backbone amides or positively charged residues is directly related to the enzyme activity and substrate binding. In ligand-bound structures of Mₚro, the oxyanion hole consists of loop (residues 140–145), negatively charged residues Glu166, positively charged residues His41, His163 and His172 remains in an active conformation (Figure 1E) (Dai et al., 2020). A π–π stacking interaction (Phe140/His163) is found in the oxyanion hole. A hydrogen bond and salt bridge involving Glu166 and His172 at the domain II further stabilize the oxyanion hole. However, the oxyanion loop (residues 137–145) is less well ordered and the side chains of Glu166 and Phe140 cannot be fit well due to poor density in our apo state structure. The salt bridge and π–π stacking interactions between Glu166/His172 and Phe140/His163 are broken, resulting in rearrangements in this region and further collapses of the oxyanion hole (Figure 1F).

The N-finger plays an important role in the formation of the active site and auto cleavage activity of Mₚro (Hilgenfeld, 2014). Gly2 has interactions with Gly143 in the oxyanion loop in the neighboring protomer, stabilizing the active site and dimer in the active conformation, while the electron density of Gly2 is completely missing in our structure. Interestingly, His163 forms hydrogen bonds with water molecular (Water 1) in our structure, which is not observed in the ligand-bound structures. Another unprecedent water molecular (Water 2) is found near Cys145-His41 catalytic dyad in the active site, working as bridge for proton transfer. We speculate that these water molecules may affect the negatively charged oxygen of the substrate or inhibitor, which suffers from steric hindrance, making rational drug design more difficult (Figure 1D–F).

In summary, we determined the apo state structure of Mₚro for SARS-CoV-2 under conditions close to the physiological state. The comparisons of Mₚro in different states reveal that the substrate binding site and the active site are more flexible in the apo state than that in the ligand-bound structures. Our structure does reveal that for drug discovery campaigns, the water molecules imbedded in the oxyanion hole and the corresponding interactions should be taken into consideration. Two water molecules are present in the oxyanion hole in our apo state structure, whereas in the ligand-bound structure, water molecular is absence in the same region. The water molecules, which is found near His163 and His41 in the occluded pocket, stabilizes the positively charged His residues, increasing the steric hindrance that may affect the catalytic efficiency of the enzyme. Altogether, the apo state structure of Mₚro for SARS-CoV-2 is an important complementary to the available structures. This structure provides novel and important insights that have broad implications for understanding the structural basis underlying enzyme activity, and can facilitate rational and structure-based approaches for the design of specific SARS-CoV-2 ligands as new therapeutic agents.
Ye, S., Pang, H., et al. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 100, 13190–13195.

Zumla, A., Chan, J.F.W., Azhar, E.I., Hui, D.S.C., and Yuen, K.Y. (2016). Coronaviruses—Drug discovery and therapeutic options. Nat Rev Drug Discov 15, 327–347.

**Supporting information**

The supporting information is available online at [https://doi.org/10.1007/s11427-020-1791-3](https://doi.org/10.1007/s11427-020-1791-3). The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.